Tue, Sep 16, 2014, 11:18 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

L & L Energy, Inc. Message Board

mitchpit11 280 posts  |  Last Activity: 5 hours ago Member since: Feb 6, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mitchpit11@gmail.com by mitchpit11 Aug 20, 2014 2:46 PM Flag

    This is just the beginning, slight positive news will get us there....

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 20, 2014 2:29 PM Flag

    Lyle, I agree with all you said.

    I think ACUR was time pressed with the FDA meeting last week which yielded two quite astonishing discoveries:

    1. FDA doesn't think there is a need for their intranasal product, i.e. there is no market for it. From shareholders point of view, one could ask Bob and Pete: why the #$%$ did you invest our money and your time in something that doesn't have any commercial use!?

    2. FDA continues to reject ACUR's studies. Like for 301, ACUR yet again failed to provide conclusive results, which again begs the question: what the #$%$ are these clowns at ACUR doing? Why submit inconclusive results? Don't they have statistician to tell them about hypothesis testing?

    Point number 1. is truly worrisome, no insight by ACUR into trends in meth abuse, while point number 2. confirms the utter incompetence of the people leading the firm.

    It seems again like Bob and Pete are just going through motions here, collecting their fat checks and bonuses, producing nothing while pretending they are doing something.

    Yes, next year the loan will need to be serviced and yes the only salvation short term is partnership.
    Oh, BTW, soon they will get Nasdaq warning for delisting, if stocks stays below $1.
    Oxecta THE ONLY hope.

  • mitchpit11@gmail.com mitchpit11 Aug 20, 2014 11:08 AM Flag

    "These days, I do not see Nexafed in any of Publix pharmacies visited."

    Here is a bit of a good news:

    Yesterday, while passing by Pharmacy in my local Publix I saw Nexafed being stocked there!
    I was quite surprised, because they didn't have it for a long time.

    Sentiment: Buy

  • mitchpit11@gmail.com mitchpit11 Aug 20, 2014 12:32 AM Flag

    1. Frank Salvado mentioned Fast Track, which is designation FDA gave for GALT, but might have confused it with other 3 "fast tracks". CNBC mentioned fast track too, and made the same confusion, i.e. mixing Fast Track while talking about FDA's fast track to drug approval. Now, whether Frank made this slight imprecision on purpose, I do not know.
    For our readers here, FDA has 4 designations for speed up drug approval process:

    Fast Track
    Breakthrough Therapy
    Accelerated Approval
    Priority Review

    It is not rocket science, as AF and you want to present it. I didn't know about it, so thank you
    for pointing out.

    2. I see no reason not to believe Teheran University research. They published it in peer reviewed Asian journal.

    3. FDA is after people who claim cancer cures in order to make a quick buck. Obviously it is not a blanket statement on pectin, otherwise they would not give fast track status to GALT.

    4. You asked me to up my game. I have no game to play, just trying to battle what I see as an unjust attack on GALT by AF/SA short sellers. And maybe you know these guys or are
    one of them.

    But, here is one question for you: what do you think of LJPC and their news of July 15:

    La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
    They use a form of pectin too.
    Your conjecture is that pectin is totally useless.
    So, is LJPC doomed ?

    Sentiment: Strong Buy

  • Ovarian cancer is one of the deadliest cancers because it’s often detected at a late stage, with higher risk of resistance to frontline chemotherapy drugs such as paclitaxel (commonly sold as Taxol). However, a new preclinical study from the University of Tehran and the Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, published in the Asian Pacific Journal of Cancer Prevention showed that Modified Citrus Pectin (MCP) increased the effectiveness of paclitaxel against ovarian cancer cells. Results showed MCP worked through its ability to block excess galectin-3 proteins.

    This study furthers our understanding of how excess galectin-3 fuels the growth and spread of chemo-resistant cancer. The study showed for the first time that galectin-3 increases ovarian cancer cell proliferation and adhesion to collagen, and further substantiated previous findings that galectin-3 prevents apoptosis in cancer cells. (Apoptosis is the normal programmed cell death in a cell’s life cycle.) Moreover, the study showed that inhibition of galectin-3 by MCP sensitizes ovarian cancer cells to the chemotherapy drug. The anti-apoptosis effect of galectin-3 was reversed in the presence of MCP.

    This study demonstrated that MCP may be a useful therapeutic agent in combination therapy for ovarian cancer. The authors note, “As paclitaxel has serious side effects, any agent that may lead to more effective cytotoxic effect or use of lower dose of this agent may be an interesting candidate for combination therapy. Our study demonstrated that MCP can sensitize ovarian cancer cells to paclitaxel through inducing apoptosis, suggesting that the combined use of MCP and paclitaxel may be an effective way to decrease the dose of paclitaxel taken.”

    As research into galectin-3 continues, MCP gains further recognition as an effective natural galectin-3 inhibitor, shown in preclinical and clinical studies to block the growth and spread of prostate, breast, and other types of cancer. MCP has also been shown to work synergistically with other anti-cancer drugs, increasing the effectiveness of doxorubicin, cisplatin, dexamethasone, as well as botanical therapies for both breast and prostate cancer.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 19, 2014 1:20 PM Flag

    Can you provide the exact CNBC quote by pointing to the article where it appeared. Thanks.

    Sentiment: Strong Buy

  • American International Group, Inc. (AIG) insurers have introduced a new policy endorsement that ensures primary directors and officers (D&O) policy funds are immediately available to clients named as defendants in securities lawsuits for the preparation of “event studies.”

    The endorsement was developed in anticipation of the U.S. Supreme Court’s June 23, 2014 decision in Halliburton Co. v Erica P. John Fund, Inc., which places added importance on costly event studies early in the litigation process as a way to determine whether securities actions can be certified as a class.

    AIG, one of the largest D&O carriers in the world, said it is first to market with this new D&O policy endorsement. The endorsement has no retention requirement. Additional premiums are not required.

    In Halliburton, the Supreme Court addressed a significant challenge to the long-standing “fraud on the market” theory in class action litigation. The theory asserts that the price of shares traded in an “efficient market” reflects all available information, including alleged misrepresentations by defendants, so that investors are presumed to have relied on those alleged misrepresentations when making their investment. This presumption effectively allowed plaintiffs to bring securities suits as class actions.

    In the ruling, the court declined to reject the fraud on the market theory entirely. It held, however, that defendants were entitled to rebut plaintiff’s presumption of reliance on the theory with evidence that alleged misstatements had no ”price impact” on share value. Presenting this evidence, in the form of event studies prepared by expert economists, may lead to significant costs for plaintiffs and defendants early in the litigation process.

    “During the Halliburton oral argument, we noted several Justices mention the event study as a form of expert evidence to assess price impact. We felt if the Court left fraud on the market standing, it would probably permit the parties to produce event studies in defense of the class certification process,” said Chris Sparro, president, Financial Lines for AIG’s Americas Region. “We created our endorsement to provide funds to our clients, free of retention requirements, so they could obtain the event studies early in the litigation process, potentially to head off class certification.”

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 19, 2014 11:54 AM Flag

    Welcome to the post June 23. 2014 world!

    FYI, I'll repost an article how insurance companies are preparing for it.
    They put their money in pre-trial phase, but for you it is just a bone.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 19, 2014 11:30 AM Flag

    Plaintiffs can argue the whole day long, but they need to prove it.
    How to prove it? It is quite tricky. Maybe impossible.

    For example, every day there were short sellers on the market.
    They obviously were not "duped".
    Then, majority of longs bought simply
    because they like to company prospects and never read promotion
    Then you have robotic algo traders, they pick on any price move, up or down.
    Then you have short term traders....
    Then you have option traders...
    Then you have index funds who need to adjust positions constantly
    Then you have ETF's, same as index funds...
    and on and on....

    I am sure GALT will have much easier time to prove stock manipulation by AF and his gang. July 25 short interest is huge red flag.

    But, back to your question, in the end, the issues are:

    1. What % of stock rise was caused by the alleged misrepresentation?

    2. What % of investment public bought the stock based on the promotional articles? Those that read it and acted by purchasing stock.

    I bet in both on these questions that %, if measurable, is quite small indeed, probably less than 1%.

    The judge should throw the case out.

    Sentiment: Strong Buy

  • Reply to

    Comical: #$%$ AF Exposed, Whines Like a Baby

    by mitchpit11 Aug 19, 2014 9:20 AM
    mitchpit11@gmail.com mitchpit11 Aug 19, 2014 9:51 AM Flag

    AF is just a media part of a well organized group of short sellers and stock manipulators.

    He is given exposure because his articles serve the purpose: to fleece investment public through lies and smears.

    If you noticed, AF is the most successful when giving negative comments, like in the case of GALT.
    His articles do not move stocks up, only down.

    But why do such articles cause so much damage, especially coming from somebody whose education stopped at BS in political science?
    Well, it is precisely because AF does not act alone, and before he published, large short positions
    are already established. Look at July 25 short interest of GALT, as one example.

    And lastly, your point about AF not being expert to give advise.
    Again, that is precisely what is needed for this group, as no serious scientist with a shred of credibility would issue such blanket statements as AF would.

    AF should be seen as a joke he is. Nothing more and probably a lot less.

    Sentiment: Strong Buy

  • Adam Feuerstein adamfeuerstein · 10h
    How much does Rod Martin pay FJRSalvato to promote GALT?

    Adam Feuerstein adamfeuerstein · 10h
    GALT vice-chair Rod Martin is a contributor to FJRSalvato right-wing web sites. … Nice try, Frank.

    Adam Feuerstein adamfeuerstein · 11h
    . PropThinker FJRSalvato isn’t making much with his right-wing loony books …
    Hence “non profit executive."

    Adam Feuerstein adamfeuerstein · 11h
    . FJRSalvato By the way, you have no idea what FDA Fast Track status means. Stick to bashing muslims.

    Adam Feuerstein adamfeuerstein · 11h
    . FJRSalvato I get a paycheck twice a month from TheStreet. You? Tell us about your financial ties to GALT and its executives

    Adam Feuerstein adamfeuerstein · 11h
    . FJRSalvato — RT PropThinker: adamfeuerstein Self-described PR exec and for some reason has interest in GALT.

    Adam Feuerstein adamfeuerstein · 11h
    . FJRSalvato Who’s paying you, Frank?

    Adam Feuerstein @adamfeuerstein · 11h
    Dumb #$%$ -- FJRSalvato

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 19, 2014 8:50 AM Flag

    Read the sentence before that one.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 19, 2014 7:55 AM Flag

    Yahoo does not allow me to post the rest of article, but worthy to find it online and read.

    AF is going ballistic on his twitter....Salvato hit the nerve, for sure...

    Sentiment: Strong Buy

  • In the movie Wall Street, the character Gordon Gecko expounds to an audience of shareholders, “Greed is good.” Gecko, a Wall Street tyrant whose specialty was destroying companies for profit, eventually gets his due in the end. But there are real life market manipulators that prowl the shadows of Wall Street and in the genre of biotech the greed of the market manipulators sometimes kills.

    People with a cursory understanding of market manipulation understand the tactic of “short and distort.” This is a type of securities fraud in which market manipulators short sell a stock and then spread negative rumors about the company in an attempt to drive down stock prices. Sometimes this fraud is originated by a company’s competitors. Other times it is fueled exclusively by greed. And while a successful short and distort campaign may glean hefty rewards for those who perpetrate the crime, the fiscal malfeasance is often fatal for the company that is attacked.

    A good example of this is playing out in real time.

    On Monday, July 30, 2014, Galectin Therapeutics, a company working on a promising avenue in the fight against kidney, liver and lung fibrosis, as well as melanoma, issued a statement about findings from a cohort 2, phase 1 drug trial. The company has received “fast track” status from the FDA. CNBC reports that no FDA fast tracked drug that has advanced to “breakthrough drug” status has failed to come to market. And with excellent cohort 1 results, it appeared as though the company was well on the way to developing cures for diseases which exist today as terminal. But while the results of the cohort 2 trial were considered positive in the eyes of subject experts, the market manipulators saw an opportunity to defraud the investors and the public, inflicting tremendous damage on the company and the company’s work on a cure for these diseases.

    Sentiment: Strong Buy

  • Reply to


    by lawrenceschaefer250 Aug 18, 2014 3:16 PM
    mitchpit11@gmail.com mitchpit11 Aug 18, 2014 8:55 PM Flag

    I know, I know....looks terrible...but remove your outright hatred for insiders (I don't blame you) and look
    at things cool headed:

    This Titanic has one more year of smooth sailing if nothing happens from now on.

    However, partnership HAS TO happen. The most we should wait is 3-4 months.

    There will be a partner for Oxecta, that is almost a certainty, Bob and Pete are not that stupid to let this opportunity slip.

    Partnership brings $10-20M upfront payment which should cause ACUR to pop over $2+, at least temporarily.

    I am looking to purchase shares one of these days...

    Sentiment: Buy

  • mitchpit11@gmail.com by mitchpit11 Aug 18, 2014 8:38 PM Flag

    Can GALT soon shine as it has much higher upside potential and addresses NASH + cancer?

    Comments on ICPT:
    We are initiating coverage of Intercept Pharmaceuticals, Inc. with an Underperform rating and a 12-month price target of $172 per share. We believe investors are much too optimistic about the accessibility of the nonalcoholic steatohepatitis (NASH) market and the regulatory pathway to commercialization. We agree that NASH is a highly prevalent disease globally but see this potential market as facing significant challenges before it can be accessed. We think payors are unlikely to embrace intervention for NASH, especially given the anticipated hepatitis C (HCV) burden on the system. NASH would be competing with HCV for payor dollars and provider access, as both diseases are treated by hepatologists.

    Furthermore, unlike HCV, which is cured after one course of treatment, NASH is likely to require chronic therapy. NASH is also a relatively unrecognized disease with no treatment paradigms, necessitating building the market. Despite compelling efficacy, we do not think the FDA is likely to approve obeticholic acid (OCA) without an adequate safety database, making an accelerated approval unlikely in the time frame expected by investors. The co-morbidities in this patient population are too significant, and the lipid changes with OCA are concerning, especially in light of the reported cardiovascular events disclosed in the top-line FLINT data release

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 16, 2014 10:26 PM Flag

    It is not just a bone:
    Conflicting views about Basic's logic among the justices nonetheless yielded a "unanimous" outcome. Neither party got exactly what it sought. Plaintiffs retained the presumption that makes securities fraud class actions possible, but successfully pursuing those claims has become harder and probably more expensive. How much so is obviously unclear. Class certification motion practice will take on even more significance. The first time a district court denies class certification because a defendant's event study shows that an alleged misstatement did not impact the stock's price could provide additional insights

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 16, 2014 9:50 PM Flag

    That very question, about how to handle class-action lawsuits by stockholders, did in fact go all the way up to United States Supreme Court. Important? Very. Here’s why: No single stockholder has the resources to sue for his/her individual losses. These lawsuits take thousands of attorney-hours to litigate. Now, not only can corporations shut down class action lawsuits faster, but they can also do it for less money. Now, at the very early stages, these class action lawsuits can be dismissed. And there’s more: The entire and only legal theory upon which these class action lawsuits are based, the “fraud on the market” theory, has been gutted.

    Sentiment: Strong Buy

  • Below is a comment from a legal expert regarding recent Supreme Court decision about securities Class action lawsuits:

    The recent decision allows corporations to file motions to dismiss at the early stages. It also enunciates some powerful grounds making such dismissal motions very likely. Previously the law permitted a presumption of securities fraud just by alleging, that is accusing the corporation of trying to effect stock prices by making public announcements. The rules have now all changed, making all these suits more difficult to win and subject to early dismissal. This is consistent with earlier decisions by the Supreme Court. Over recent years, the court has limited workers and consumer class action lawsuits and this recent decision reads consistent with previous decisions affecting consumer and workers. Class actions bode well for a continuing trend: the law now requires more proof and earlier proof by plaintiffs to get the case in front of a jury.

    Sentiment: Strong Buy

  • mitchpit11@gmail.com mitchpit11 Aug 15, 2014 2:03 PM Flag

    Thank you for your input.

    The question is not whether there are better molecules, there is always something better, but whether the current track GALT is on will lead to marketable drug(s)?

    What is your opinion?

    Sentiment: Strong Buy

0.1241-0.0059(-4.54%)Sep 16 3:45 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.